ArticleFrontiers in pharmacology2022

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.

Yi Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.